首页> 外文期刊>Journal of Medical Case Reports >Adult growth hormone deficiency treatment with a combination of growth hormone and insulin-like growth factor-1 resulting in elevated sustainable insulin-like growth factor-1 and insulin-like growth factor binding protein 3 plasma levels: a case report
【24h】

Adult growth hormone deficiency treatment with a combination of growth hormone and insulin-like growth factor-1 resulting in elevated sustainable insulin-like growth factor-1 and insulin-like growth factor binding protein 3 plasma levels: a case report

机译:结合生长激素和胰岛素样生长因子-1的成人生长激素缺乏症治疗,导致可持续的胰岛素样生长因子-1和胰岛素样生长因子结合蛋白3血浆水平升高:一例

获取原文
       

摘要

Introduction Adult Growth hormone Deficiency is a well known phenomenon effecting both males and females. Adult Growth Hormone Deficiency is marked by a number of neuropsychiatric, cognitive performance, cardiac, metabolic, muscular, and bone symptoms and clinical features. There is no known standardized acceptable therapeutic modality to treat this condition. A recent meta-analysis found that after 16 years of Growth Hormone replacement therapy a large proportion of the patients still had Growth Hormone associated symptoms especially related to executive functioning. A major goal is to increase plasma levels of both insulin-like growth factor (insulin-like growth factor-1) and insulin-like growth factor binding protein 3. Case Presentation We report a case of a 45-year-old caucasian woman with early ovarian failure for 2 years and amenorrhea since the age of 43, who presented with Adult Growth Hormone Deficiency and an IGF-1 of 126 ng/mL. Since her insulin-like growth factor-1 was lowest at 81 ng/mL, she was started on insulin-like growth factor-1 Increlex at 0.2 mg at bedtime, which immediately raised her insulin-like growth factor-1 levels to 130 ng/mL within 1 month, and 193 ng/mL, 249 ng/mL, and 357 ng/mL, after 3, 4, and 5 months, respectively, thereafter. Her insulin-like growth factor binding protein 3 continued to decrease. It was at this point when we added back the Growth Hormone and increased her Increlex dosage to 1.3 - 1.5 mg that her insulin-like growth factor binding protein 3 began to increase. Conclusion It appears that in some patients with Adult Growth Hormone Deficiency, insulin-like growth factor-1 elevation is resistant to direct Growth Hormone treatment. Furthermore, the binding protein may not rise with insulin-like growth factor-1. However, a combination of Growth Hormone and insulin-like growth factor-1 treatment may be a solution.
机译:简介成人生长激素缺乏症是一种众所周知的现象,对男性和女性都有影响。成人生长激素缺乏症的特征是许多神经精神病学,认知表现,心脏,代谢,肌肉和骨骼症状以及临床特征。没有已知的标准化可接受的治疗方式可以治疗这种疾病。最近的一项荟萃​​分析发现,生长激素替代疗法16年后,仍有很大一部分患者仍具有生长激素相关症状,尤其是与执行功能有关。一个主要目标是增加血浆中胰岛素样生长因子(insulin-like growth factor-1)和胰岛素样生长因子结合蛋白3的水平。病例报告我们报道了一名45岁的白人妇女卵巢早衰2年,自43岁起出现闭经,表现为成人生长激素缺乏症和IGF-1为126 ng / mL。由于她的胰岛素样生长因子-1最低,为81 ng / mL,因此她在睡前以0.2 mg的胰岛素样生长因子-1 Increlex开始服用,这立即使她的胰岛素样生长因子1水平升至130 ng。分别在1个月内升高到/ mL,在分别3、4和5个月后分别升高到193 ng / mL,249 ng / mL和357 ng / mL。她的胰岛素样生长因子结合蛋白3继续减少。正是在这一点上,当我们重新添加生长激素并将其Increlex剂量增加至1.3-1.5 mg时,她的胰岛素样生长因子结合蛋白3开始增加。结论在某些成人生长激素缺乏症患者中,胰岛素样生长因子1升高对直接生长激素治疗有抵抗力。此外,结合蛋白可能不会随胰岛素样生长因子-1升高。但是,生长激素和胰岛素样生长因子-1治疗的组合可能是一种解决方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号